<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Poster: Using PDX for In Vivo CAR-T Cell Therapy Assessment

Efficient growth suppression of pancreatic cancer PDX by fully human anti-mesothelin CAR-T cells

Jiang Hua*, Bo Song#, Peng Wang#, Qixiang Li, and Zonghai Li*#
*State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
#CARsgen Therapeutics, Suite 401, Building 3, 466 Yindu Road, Xuhui District, Shanghai

Poster: Using PDX for In Vivo CAR-T Cell Therapy AssessmentThere’s a growing interest in using CAR-T cell therapies for solid tumors as well as haematological malignancies. One such cancer subtype may be pancreatic cancer, which lacks curable treatment options, and is complicated by a hostile stroma microenvironment.

A potential new drug target which is highly expressed in pancreatic cancer is mesothelin. Mesothelin is a promising target for antitumour therapies including antibodies, vaccines, antibody-drug conjugates, as well as immunotherapies.

This poster details the development of a novel CAR-T cell therapy targeting mesothelin for pancreatic cancer treatment. Antitumour activity in vitro, using mesothelin-expressing cancer cells, as well in vivo, using a mesothelin-expressing patient-derived xenograft (PDX) model, is assessed.

Read this Poster to Discover:

  • That CAR-Mesothelin T cells efficiently lyse mesothelin-positive pancreatic cancer cells, but not mesothelin-negative cells in vitro

  • That higher levels of INF-α, IL-2, and IFN-γ are expressed by CAR-Mesothelin T cells with the stimulation of mesothelin-positive pancreatic cancer cells, as compared to mock T cells

  • How mesothelin-positive pancreatic PDX model tumour growth is suppressed by CAR-Mesothelin T cells, with tumour infiltration of CAR-T cells observed

Download the Poster Now!



Download Now

Your privacy is important to us.
We'll never share your information.